Standex International: Great Business, Expensive Stock at 61x Earnings

Standex still looks strong, but 61x earnings leaves little room for error

Standex remains a high-quality industrial. But at about 61.10 price-to-earnings, with a $2.98B market cap and shares near the $284.71 52-week high, this is no longer a discovery trade. The easy part-showing the business is good-is already reflected in the price. Now investors are paying for consistency before the next stretch of earnings arrives.

Why the setup has changed

Bulls can still point to record fiscal 2026 results and management's more confident FY27 outlook. That matters, because the bull case is rooted in execution, not in a comeback narrative. Still, once a stock trades at 61.10x earnings near its 52-week high, durability by itself may not be enough. The real debate is whether sustained growth and margins can justify a premium multiple that already assumes a clean run of quarters.

Strong fundamentals are supporting the premium

New-product sales have been the clearest quality signal

The key point is not just that Standex grew. It is that the mix kept improving. New-product sales grew 43% in Q4 FY26, roughly 40% in Q3, and were above 35% in Q1. That matters because new-product demand usually reflects stronger product-market fit and can support better pricing and margin resilience than legacy demand.

Fast-growth-market sales reinforce the same point. They contributed ~30% of total sales in Q1, >30% of total sales in Q3, and 31% of total sales in Q4. In other words, a meaningful and stable share of revenue was already coming from higher-value applications rather than older, more commoditized pockets of demand.

Order health has held up across quarters

Demand was not limited to a single quarter. Book-to-bill was 1.06 in Q1, 1.05 in Q3, 1.18 overall in Q4, and 1.27 in Electronics in Q4. Management also reported record order intake of ~$270 million in Q4.

That is the mechanism bulls are looking for: stronger intake converts into revenue, then into operating leverage. When book-to-bill stays above 1.0 across quarters, investors can underwrite the next few periods with more confidence.

Margins improved while leverage declined

The operational story also improved on profitability. Adjusted operating margin rose from 19.1% in Q1 to 19.7% in Q3 and 19.9% in Q4. Standex also ended FY26 with record adjusted gross margin and adjusted operating margin.

The balance sheet improved over the same period. Net debt to EBITDA was 2.4x in Q1 and fell to 1.9x in Q3. For a niche industrial compounder, that is what maturity should look like: stronger earnings power, less leverage, and more capital flexibility.

The valuation now depends on the next few quarters

At this level, the market is valuing future earnings heavily. A $2.98B market cap at 61.10 price-to-earnings implies roughly $9.96 of trailing earnings. Recent results support the idea that Standex can still deliver clean prints: the company posted a 4.26% EPS surprise in Q4 and had three EPS beats in four quarters. But when a stock trades at a premium multiple, beats alone are not enough. The commentary around those beats matters just as much.

What could pressure the multiple

The bear case does not require a broken business. It only requires growth or margins to flatten while the stock still trades as though execution will stay perfect. One clear benchmark is whether Standex can build on more than 20 new product launches and keep fast-growth demand durable enough to support the premium. If that happens, the stock can stay justified. If not, even a strong company can become an expensive trade.